Combination therapy for cancer

The invention relates generally to a combination therapy for the treatment of cancer, particularly to a combination of (i) a bifunctional molecule comprising a TGF[beta]RII or fragment thereof capableof binding TGF[beta] and an antibody, or antigen binding fragment thereof, that binds to an immune c...

Full description

Saved in:
Bibliographic Details
Main Authors LAN YAN, LO KIN MING
Format Patent
LanguageChinese
English
Published 16.04.2019
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention relates generally to a combination therapy for the treatment of cancer, particularly to a combination of (i) a bifunctional molecule comprising a TGF[beta]RII or fragment thereof capableof binding TGF[beta] and an antibody, or antigen binding fragment thereof, that binds to an immune checkpoint protein, such as Programmed Death Ligand 1 (PD-L1) and (ii) at least one additional anti-cancer therapeutic agent. 本发明总体涉及用于治疗癌症的联合疗法，尤其以下所述的联合：(i)双功能分子，其包含TGFβRII或其能够结合TGFβ的片段和结合免疫哨点蛋白例如程序性死亡配体1(PD-L1)的抗体或其抗原结合片段和(ii)至少种其他抗癌治疗剂。
Bibliography:Application Number: CN201780049391